Therefore, the observed associations between the expressions of the SEMA7A, SEMA4D, ADAM8, and ADAMTS10 in tumor groups with KRAS, NRAS, BRAF, PIK3CA, and AKT mutations require validation in larger study cohorts. This evidence concerns the gene SEMA4D and neoplasm.